<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04959851</url>
  </required_header>
  <id_info>
    <org_study_id>MACS-2021-011101</org_study_id>
    <nct_id>NCT04959851</nct_id>
  </id_info>
  <brief_title>A Study on How Vedolizumab is Given and the Outcomes for Adults With Inflammatory Bowel Disease (VARIETY-Belgium)</brief_title>
  <official_title>Prospective, Non-Interventional, Observational Study in Patients With IBD Receiving IV or SC Vedolizumab Therapy to Observe Route of Administration Choices and Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      IBD consists of either ulcerative colitis or Crohn's disease.&#xD;
&#xD;
      The main aim of this study is to describe real-world treatment patterns in adults with&#xD;
      moderate to severe ulcerative colitis or Crohn's disease when treated with vedolizumab. This&#xD;
      will include how vedolizumab is given, which can either be an infusion through a vein&#xD;
      (intravenous or IV), or an injection just under the skin (subcutaneous injection, or SC).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a non-interventional, prospective study of participants with moderately to severely&#xD;
      active IBD (UC or CD) who are initiating or currently ongoing induction or maintenance&#xD;
      treatment with vedolizumab according to the current SmPC in the real world setting.&#xD;
&#xD;
      The study will enroll approximately 200 participants. The data will be collected&#xD;
      prospectively and will be recorded into electronic case report forms (e-CRFs). All the&#xD;
      participants will be assigned to a single observational cohort:&#xD;
&#xD;
      • Participants with IBD&#xD;
&#xD;
      This multi-center study will be conducted in Belgium at specialized gastroenterology centers.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">April 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Persisting to Treatment With Vedolizumab IV Compared to Participants With Treatment Change Up to 12 Months</measure>
    <time_frame>Baseline up to 12 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to any Treatment Change</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Reason for Treatment Change</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Change in Vedolizumab Dosing Frequency</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued the Vedolizumab Treatment</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Changed to Another Treatment</measure>
    <time_frame>Baseline up to 24 months</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Inflammatory Bowel Diseases</condition>
  <condition>Colitis, Ulcerative</condition>
  <condition>Crohns Disease</condition>
  <arm_group>
    <arm_group_label>Participants With Inflammatory Bowel Disease (IBD)</arm_group_label>
    <description>Participants diagnosed with moderately to severely active IBD (UC or CD) who are initiating or currently ongoing vedolizumab intravenous induction treatment or maintenance intravenous treatment in accordance with the current Summary of Product Characteristics (SmPC) along with the option to switch to vedolizumab subcutaneous (SC) treatment, will be observed prospectively for 24 months.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Adult participants with moderately to severely active UC or CD receiving vedolizumab&#xD;
        treatment in accordance with the approved SmPC.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Has moderately to severely active IBD (UC or CD), initiating or ongoing IV induction&#xD;
        treatment with vedolizumab in accordance with the current SmPC at baseline OR IBD&#xD;
        participants receiving ongoing/maintenance IV vedolizumab treatment, with the option to&#xD;
        switch to SC vedolizumab maintenance treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior history of intolerability, hypersensitivity, or other contraindications (active&#xD;
             severe infections such as tuberculosis, sepsis, cytomegalovirus, listeriosis, and&#xD;
             opportunistic infections such as Progressive Multifocal Leukoencephalopathy) to&#xD;
             vedolizumab therapy as defined in the current SmPC.&#xD;
&#xD;
          2. Current or planned participation in an interventional clinical trial for CD or UC.&#xD;
&#xD;
          3. Cognitive incapacity, unwillingness or language barriers precluding adequate&#xD;
             understanding or cooperation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Takeda Contact</last_name>
    <phone>+1877-825-3327</phone>
    <email>medinfoUS@takeda.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>GZA St. Vincentius</name>
      <address>
        <city>Antwerpen</city>
        <zip>2018</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>03 285 20 00</phone>
      <email>Dirk.Staessen@gza.be</email>
    </contact>
    <investigator>
      <last_name>Dirk Staessen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UZA</name>
      <address>
        <city>Antwerpen</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>03 821 40 61</phone>
      <email>Elisabeth.Macken@uza.be</email>
    </contact>
    <investigator>
      <last_name>Elisabeth Macken, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasme</name>
      <address>
        <city>Bruxelles</city>
        <zip>1070</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>02 555 37 12</phone>
      <email>denis.franchimont@erasme.ulb.ac.be</email>
    </contact>
    <investigator>
      <last_name>Denis Franchimont, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ZOL</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>089 32 65 10</phone>
      <email>Philip.Caenepeel@zol.be</email>
    </contact>
    <investigator>
      <last_name>Philip Caenepeel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ St. Lucas</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>09 224 64 80</phone>
      <email>Harald.Peeters@AZSTLUCAS.BE</email>
    </contact>
    <investigator>
      <last_name>Harald Peeters, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHR Citadelle</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>04 321 70 89</phone>
      <email>Anne.Vijverman@chrcitadelle.be</email>
    </contact>
    <investigator>
      <last_name>Anne Vijverman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Liège</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>04 366 72 56</phone>
      <email>Edouard.Louis@chuliege.be</email>
    </contact>
    <investigator>
      <last_name>Edouard Louis, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHC MontLégia</name>
      <address>
        <city>Liège</city>
        <zip>400</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>04 355 50 09</phone>
      <email>Arnaud.colard@chc.be</email>
    </contact>
    <investigator>
      <last_name>Arnaud Collard, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselaere</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>051 23 71 75</phone>
      <email>filip.baert@azdelta.be</email>
    </contact>
    <investigator>
      <last_name>Filip Baert, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHWAPI</name>
      <address>
        <city>Tournai</city>
        <zip>7500</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <contact>
      <phone>069 33 31 11</phone>
      <email>Antoine.nakad@chwapi.be</email>
    </contact>
    <investigator>
      <last_name>Antoine Nakad, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <link>
    <url>https://clinicaltrials.takeda.com/study-detail/60f13cd7f883ca001e82d337</url>
    <description>To obtain more information on the study, click here/on this link</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 2, 2021</study_first_submitted>
  <study_first_submitted_qc>July 2, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 13, 2021</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Drug Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Crohn Disease</mesh_term>
    <mesh_term>Intestinal Diseases</mesh_term>
    <mesh_term>Inflammatory Bowel Diseases</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_access_criteria>IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.</ipd_access_criteria>
    <ipd_url>https://vivli.org/ourmember/takeda/</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

